Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2020

View Archived Issues

Data from SUMMIT basket trial of neratinib in HER2-mutant, metastatic cervical cancer

High-throughput fluorescence polarization screen identifies new viral fusion inhibitor, F-0045

PRC member affects blood formation during aging

New hypothalamic obesity treatment target identified

FDA approves Lampit for the treatment of Chagas disease in children

Voronoi discloses new RIP-1 kinase 1 inhibitors

Ascentage Pharma, University of Michigan present Mcl-1 inhibitors

Arbutus Biopharma identifies new hepatitis B virus HBsAg secretion inhibitors

Opdivo plus Yervoy show durable survival benefit in CheckMate-743 study

Beijing Xuanyi Pharmasciences patents GABA(A) receptor subunits alpha1beta2gamma2 PAMs

Jiangsu Chia Tai Tianqing Pharmaceutical Group discovers HBV caspid assembly inhibitors

Results from phase III program of etrolizumab in moderate to severe ulcerative colitis

Sinovac's COVID-19 vaccine enters phase III testing in healthcare professionals

Daiichi Sankyo studies DS-1001b in phase II for WHO grade II glioma

Boehringer Ingelheim initiates phase II study of BI-1015550 in IPF

Phase I retinitis pigmentosa study finds N-acetylcysteine improves visual function

Novel pyrazolopyrimidine-derived CDPK1 inhibitors for the treatment of toxoplasmosis

Janssen studies JNJ-70218902 in metastatic castration-resistant prostate cancer

FDA approves Evrysdi for spinal muscular atrophy

FDA approves Olinvyk for acute pain

Pivotal study of SER-109 for C. difficile infection meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...